There are many types of kidney disease that impact on kidney function and the measure used is protein urea. Apellis drug found to have benefits for C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis does it work for other kidney diseases this is an unknown and will require clinical trails. We know drugs that work on one kidney disease may not work for others. DXB drug is for FSGS data to date indicates for FSGS suffers it reduces protein urea they are also Ph3 and way ahead of others to market.
Banter and general comments, page-23
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.015(3.61%) |
Mkt cap ! $228.3M | |||
| Open | High | Low | Value | Volume |
| 42.5¢ | 44.0¢ | 40.0¢ | $1.127M | 2.724M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 165792 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 88439 | 14 |
View Market Depth
| Last trade - 15.53pm 16/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |